Truist raised the firm’s price target on CG Oncology (CGON) to $75 from $66 and keeps a Buy rating on the shares. The firm cites its expectations for the company to disclose PIVOT-006 topline in IR NMIBC – intermediate-risk and high-risk Non-Muscle Invasive Bladder Cancer – in the first half of the year. The setting has a large addressable market and less competition, where Creto is the most advanced candidate with broad disease coverage, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology price target raised to $73 from $61 at RBC Capital
- CG Oncology price target raised to $70 from $55 at Piper Sandler
- Oncolytics appoints John McAdory as EVP, strategy and operations
- CG Oncology Expands At-The-Market Equity Offering Capacity
- Biotech Alert: Searches spiking for these stocks today